Kurzfassung

A phase III, randomized, open-label study of the efficacy and safety of Crizotinib versus Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in previously untreated patients with Non-Squamous Carcinoma of the Lung harboring a translocation or inversion event involving the Anaplastic Lymphoma Kinase (ALK) gene locus